Insights - Just in front of its option deadline, Celgene (CELG) has re-upped on an existing research and discovery collaboration with Epizyme (EPZM), a developer of targeted cancer … Continue Reading
Read NowInsights - Horizon Pharma (HZNP) has gone hostile in its attempt to acquire Depomed (DEPO), offering $29.25 in HZNP stock, or $3 billion, for the smaller specialty … Continue Reading
Read NowInsights - It’s one of the most elusive events in biotech: the liquidation. But after a trial failure of epic proportions – and a collapse in its stock … Continue Reading
Read NowInsights - Two drugs directed at behavioral disorders failed mid-stage studies on Wednesday morning, said sponsors Alcobra (ADHD) and Transition Therapeutics (TTHI), yet again highlighting the difficulty in developing drugs for disorders involving the Central Nervous System.
Read NowInsights - Titan Pharmaceuticals’ (TTNP) implantable device for the treatment of opioid addiction performed as well as standard sublingual buprenorphine tablets in a phase 3 study, the … Continue Reading
Read NowRecap - For this Memorial Day and a long weekend with family & friends, we’re offering YOU $100 off an annual subscription to our premier investing newsletter – PropThink … Continue Reading
Read NowRecap - Last week’s biotech recap covered the release of briefing documents from Vertex Pharmaceuticals’ (VRTX) advisory panel, which took place this Tuesday. The FDA’s Pulmonary-Allergy Drugs Advisory Committee voted … Continue Reading
Read Now
